The assessment of cardiovascular risk and treatment of cardiovascular diseases are major public health issues worldwide. Inflammation is now recognized as a key regulatory process that links multiple risk factors for atherosclerosis. The substantial number of patients having cardiovascular events lack commonly established risk factors. The utility of high-sensitivity C-reactive protein (hsCRP), a circulating biomarker related to inflammation, may provide additional information in risk prediction. This review will consider the impact of hsCRP level on initiation of statin therapy.
Lloyd-JonesDM. Cardiovascular risk prediction: basic concepts, current status, and future directions. Circulation. 2010;121(15):1768–1777.
2.
SmithSCJr.Current and future directions of cardiovascular risk prediction. Am J Cardiol. 2006;97(2A):28A–32A.
3.
MarcovinaSMCreaFDavignonJ. Biochemical and bioimaging markers for risk assessment and diagnosis in major cardiovascular diseases: a road to integration of complementary diagnostic tools. J Intern Med. 2007;261(3):214–234.
4.
AthyrosVGKakafikaAIKaragiannisAMikhailidisDP. Do we need to consider inflammatory markers when we treat atherosclerotic disease?Atherosclerosis. 2008;200(1):1–12.
5.
GreenlandPAlpertJSBellerGA. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2010;56(25):e50–e103.
6.
GenestJMcPhersonRFrohlichJ. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult—2009 recommendations. Can J Cardiol. 2009;25(10):567–579.
7.
PerkJDe BackerGGohlkeH. European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The fifth joint task force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2012;33(13):1635–1701.
8.
RiesenWFEnglerHRischMKorteWNosedaG. Short-term effects of atorvastatin on C-reactive protein. Eur Heart J. 2002;23(10):794–799.
9.
RidkerPMRifaiNPfefferMA. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events (CARE) investigators. Circulation. 1998;98(9):839–844.
10.
RidkerPMRifaiNPfefferMASacksFBraunwaldE. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The cholesterol and recurrent events (CARE) investigators. Circulation. 1999;100(3):230–235.
11.
ChuAYGuilianiniFBarrattBJNybergFChasmanDIRidkerPM. Pharmacogenetic determinants of statin-induced reductions in C-reactive protein. Circ Cardiovasc Genet. 2012;5(1):58–65.
12.
RidkerPMRifaiNClearfieldM. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 2001;344(26):1959–1965.
13.
RidkerPMDanielsonEFonsecaFA. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195–2207.
14.
RidkerPMDanielsonEFonsecaFA. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet. 2009;373(9670):1175–1182.
15.
RidkerPMMacFadyenJLibbyPGlynnRJ. Relation of baseline high-sensitivity C-reactive protein level to cardiovascular outcomes with rosuvastatin in the Justification for use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER). Am J Cardiol. 2010;106(2):204–209.
16.
KappagodaCTAmsterdamEA. Another look at the results of the JUPITER trial. Am J Cardiol. 2009;104(11):1603–1605.
17.
KaulSMorrisseyRPDiamondGA. By Jove! What is a clinician to make of JUPITER?Arch Intern Med. 2010;170(12):1073–1077.
18.
de LorgerilMSalenPAbramsonJ. Cholesterol lowering, cardiovascular diseases, and the rosuvastatin-JUPITER controversy: a critical reappraisal. Arch Intern Med. 2010;170(12):1032–1036.
19.
JonathanEDerrickBEmmaL. C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20,536 patients in the heart protection study. Lancet. 2011;377(9764):469–476.
20.
SattarNMurrayHMMcConnachieA. C-reactive protein and prediction of coronary heart disease and global vascular events in the prospective study of pravastatin in the elderly at risk (PROSPER). Circulation. 2007;115(8):981–989.
21.
SeverPSPoulterNRChangCL. Evaluation of C-reactive protein prior to and on-treatment as a predictor of benefit from atorvastatin: observations from the Anglo-Scandinavian cardiac outcomes trial. Eur Heart J. 2012;33(4):486–494.
22.
RidkerPMGlynnRJ. The JUPITER Trial: responding to the critics. Am J Cardiol. 2010;106(9):1351–1356.
23.
MyersGLChristensonRHCushmanM. National academy of clinical biochemistry laboratory medicine practice guidelines: emerging biomarkers for primary prevention of cardiovascular disease. Clin Chem. 2009;55(2):378–384.
24.
RidkerPMMorrowDARoseLMRifaiNCannonCPBraunwaldE. Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial. J Am Coll Cardiol. 2005;45(10):1644–1648.
25.
RidkerPMCannonCPMorrowD. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352(1):20–28.
26.
NissenSETuzcuEMSchoenhagenP. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med. 2005;352(1):29–38.
27.
MorrowDAde LemosJASabatineMS. Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial. Circulation. 2006;114(4):281–288.
28.
PearsonTAMensahGAAlexanderRW. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the centers for disease control and prevention and the American heart association. Circulation. 2003;107(3):499–511.
29.
SabatineMSMorrowDAJablonskiKA. Prognostic significance of the centers for disease control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease. Circulation. 2007;115(12):1528–1536.
30.
SciricaBMMorrowDACannonCP. Clinical application of C-reactive protein across the spectrum of acute coronary syndromes. Clin Chem. 2007;53(10):1800–1807.
31.
KhotUNKhotMBBajzerCT. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA. 2003;290(7):898–904.
32.
BuckleyDIFuRFreemanMRogersKHelfandM. C-reactive protein as a risk factor for coronary heart disease: a systematic review and meta-analyses for the U.S. preventive services task force. Ann Intern Med. 2009;151(7):483–495.
33.
MohlenkampSLehmannNMoebusS. Quantification of coronary atherosclerosis and inflammation to predict coronary events and all-cause mortality. J Am Coll Cardiol. 2011;57(13):1455–1464.
34.
Using nontraditional risk factors in coronary heart disease risk assessment: U.S. preventive services task force recommendation statement. Ann Intern Med. 2009;151(7):474–482.
35.
BogatyPBrophyJMBoyerL. Fluctuating inflammatory markers in patients with stable ischemic heart disease. Arch Intern Med. 2005;165(2):221–226.
36.
KaptogeSDi AngelantonioEPennellsL. C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med. 2012;367(14):1310–1320.
37.
RidkerPMPaynterNPRifaiNGazianoJMCookNR. C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds risk score for men. Circulation. 2008;118(22):2243–2251.
38.
RidkerPMBuringJERifaiNCookNR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds risk score. JAMA. 2007;297(6):611–619.
